STOCK TITAN

Cytokinetics Stock Price, News & Analysis

CYTK NASDAQ

Company Description

Overview of Cytokinetics Inc

Cytokinetics Inc (CYTK) is a late-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of first-in-class, muscle activator therapies. Specializing in muscle biology and small molecule therapeutics, the company focuses on treatments designed to improve muscle function and contractility, addressing critical challenges in cardiovascular and neuromuscular diseases.

Core Business and Therapeutic Focus

Cytokinetics operates at the intersection of science and medicine by targeting debilitating diseases characterized by reduced muscle performance. With a strategic emphasis on conditions such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases, the company leverages extensive research in muscle mechanics to engineer drug candidates that enhance muscle contractility, thus offering potential therapeutic benefits in diseases where muscle weakness and fatigue are prevalent.

Scientific and Technological Expertise

The company’s deep expertise in muscle biology enables it to design small molecule drugs that specifically target the mechanisms underlying muscle contraction. This scientifically rigorous approach not only differentiates Cytokinetics from broader biopharmaceutical enterprises but also establishes its role as an innovator in muscle performance therapy. The use of advanced molecular techniques and proprietary screening methodologies further underscores its commitment to pushing the boundaries of current therapeutic paradigms.

Market Position and Competitive Landscape

Positioned within the competitive biotechnology and pharmaceutical sectors, Cytokinetics is recognized for its methodical approach to drug development. While the biopharmaceutical industry is crowded with companies seeking to address similar health challenges, Cytokinetics distinguishes itself by a focused expertise in muscle mechanics. This clear specialization provides investors and industry analysts with a nuanced understanding of its potential to improve the health span of patients suffering from muscle-related impairments.

Operational Strategy and Revenue Generation

The company generates revenue through a combination of strategic partnerships, collaborative research agreements, and licensing arrangements, in addition to progressing its own drug candidates through clinical development. Its operational model is rooted in methodical scientific inquiry combined with careful risk management, ensuring that even in a competitive landscape, the company sustains a robust framework of research and development that continues to contribute broadly to therapeutic innovations.

Significance in the Biotechnology Industry

Cytokinetics Inc serves as an important player within the biotechnology industry by addressing a critical unmet need: the improvement of muscle function in disease states. Its research-driven approach not only enhances the understanding of muscle physiology but also fosters the development of innovative therapies that could transform approaches to treating systemic muscle impairments. The company’s comprehensive research, rigorous scientific methodology, and clear focus on muscle activators underscore its potential to modify clinical approaches to a range of debilitating conditions.

Industry Insights and Frequently Asked Questions

Through its continuous commitment to advancing scientific knowledge and therapeutic innovation, Cytokinetics offers valuable insights into the complex interplay of muscle biology and disease treatment. The company’s efforts not only contribute to the broader discourse on muscle performance therapies but also provide a framework for understanding the future landscape of neuromuscular and cardiovascular treatment strategies.

  • Innovative Research: Emphasizes the use of advanced technologies and proprietary methods to identify and optimize small molecule candidates that directly address muscle function.
  • Surgical Focus: Clearly concentrates on diseases marked by muscle decline, placing its research at the heart of a growing need in medical therapeutics.
  • Collaborative Model: Engages with academic institutions, research organizations, and industry partners to further validate its drug development programs.

This comprehensive overview is designed to offer a deep dive into the operational and scientific dimensions of Cytokinetics Inc. Investors and market analysts can utilize this detailed background to better understand the company’s strategies, research direction, and its pivotal role in the evolving landscape of muscle biology-based therapeutics.

Stock Performance

$63.59
0.00%
0.00
Last updated: November 2, 2025 at 16:11
-37.65 %
Performance 1 year

Financial Highlights

$463,000
Revenue (TTM)
-$160,545,000
Net Income (TTM)
-$101,500,000
Operating Cash Flow
-34,674.95%

Upcoming Events

NOV
03
November 3, 2025 Corporate

Grant applications deadline

Deadline for 2025 Communications Grant applications
NOV
05
November 5, 2025 Earnings

Q3 2025 results release

Q3 2025 results release via Investors & Media site
NOV
05
November 5, 2025 Earnings

Q3 2025 earnings call

Live webcast via Investors & Media section of Cytokinetics website
NOV
07
November 7, 2025 Marketing

HCMS Scientific Sessions

Presentation at Hypertrophic Cardiomyopathy Society Scientific Sessions
NOV
07
November 7, 2025 - November 10, 2025 Marketing

AHA Scientific Sessions

Presentations at American Heart Association Scientific Sessions in New Orleans
DEC
26
December 26, 2025 Regulatory

Aficamten FDA decision

FDA PDUFA date for aficamten in obstructive HCM
DEC
26
December 26, 2025 Regulatory

PDUFA date for aficamten

DEC
26
December 26, 2025 Regulatory

PDUFA decision date

FDA review target date for aficamten approval
DEC
26
December 26, 2025 Regulatory

PDUFA date for aficamten

DEC
26
December 26, 2025 Regulatory

PDUFA decision date

FDA PDUFA date for aficamten decision

Short Interest History

Last 12 Months
Loading short interest data...

Days to Cover History

Last 12 Months
Loading days to cover data...

Frequently Asked Questions

What is the current stock price of Cytokinetics (CYTK)?

The current stock price of Cytokinetics (CYTK) is $63.59 as of October 31, 2025.

What is the market cap of Cytokinetics (CYTK)?

The market cap of Cytokinetics (CYTK) is approximately 7.4B. Learn more about what market capitalization means .

What is the revenue (TTM) of Cytokinetics (CYTK) stock?

The trailing twelve months (TTM) revenue of Cytokinetics (CYTK) is $463,000.

What is the net income of Cytokinetics (CYTK)?

The trailing twelve months (TTM) net income of Cytokinetics (CYTK) is -$160,545,000.

What is the earnings per share (EPS) of Cytokinetics (CYTK)?

The diluted earnings per share (EPS) of Cytokinetics (CYTK) is -$1.36 on a trailing twelve months (TTM) basis. Learn more about EPS .

What is the operating cash flow of Cytokinetics (CYTK)?

The operating cash flow of Cytokinetics (CYTK) is -$101,500,000. Learn about cash flow.

What is the profit margin of Cytokinetics (CYTK)?

The net profit margin of Cytokinetics (CYTK) is -34,674.95%. Learn about profit margins.

What is the operating margin of Cytokinetics (CYTK)?

The operating profit margin of Cytokinetics (CYTK) is -30,410.58%. Learn about operating margins.

What is the current ratio of Cytokinetics (CYTK)?

The current ratio of Cytokinetics (CYTK) is 9.28, indicating the company's ability to pay short-term obligations. Learn about liquidity ratios.

What is the operating income of Cytokinetics (CYTK)?

The operating income of Cytokinetics (CYTK) is -$140,801,000. Learn about operating income.

What is the primary focus of Cytokinetics Inc?

Cytokinetics Inc focuses on developing small molecule drug candidates designed to improve muscle function and contractility in conditions characterized by muscle weakness and decline.

Which diseases does Cytokinetics target with its therapeutics?

The company targets diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases, all of which are associated with reduced muscle performance.

How does Cytokinetics generate revenue?

Revenue is generated through strategic partnerships, research collaborations, and licensing arrangements, alongside advancing its proprietary drug candidates through clinical development.

What differentiates Cytokinetics from other companies in the biotechnology sector?

Its specialized focus on muscle biology and the development of muscle activators sets it apart, allowing it to target specific neuromuscular and cardiovascular conditions.

How does the company approach drug development?

Cytokinetics employs a research-driven process that integrates advanced molecular techniques with proprietary screening methods to optimize small molecule candidates for muscle function improvement.

What role does muscle biology play in Cytokinetics' therapeutic development?

Muscle biology is central to the company’s approach, as it underpins the design of its drug candidates aimed at enhancing muscle contractility and overall performance in degenerative diseases.

How does Cytokinetics contribute to the biotechnology and pharmaceutical industries?

By advancing innovative therapies based on a strong scientific understanding of muscle mechanics, Cytokinetics offers new perspectives in treating debilitating diseases that affect muscle function.

Can you explain the company’s collaborative strategy?

Cytokinetics actively engages in partnerships with research organizations and academic institutions, which supports validation and further development of its therapeutic candidates.